Kinnate Biopharma Total Liabilities

The latest total liabilities for KNTE is $14M as of December 2023. That compares with $20M in the prior-year period — down 29.9% year over year. Investors often review this figure alongside Kinnate Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, KNTE's total liabilities moved from $20M to $14M — a 29.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kinnate Biopharma's operating scale or balance-sheet position.

A total liabilities figure of $14M for KNTE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KNTE's total liabilities ($14M), review year-over-year change from $20M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Kinnate Biopharma's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.